Can delivering cancer drug directly to the liver shrink tumors?

This phase II trial is investigating whether giving the drug bevacizumab directly into the liver's main artery, alongside standard chemotherapy, can shrink liver tumors in people with colorectal cancer that has spread only to the liver. The study enrolls patients whose cancer progressed after first-line chemotherapy and who are not candidates for curative surgery. The main goal is to measure the tumor response rate, with secondary goals of assessing side effects, progression-free survival, and whether the treatment might enable later surgery.